Abbott India net profit rises to 8.5 per cent in Q1FY22
PAT rises to Rs 195.76 crore
PAT rises to Rs 195.76 crore
India business contributes to a stellar performance
Forex gains stood at Rs 20 crore for the quarter
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Advances deployment of mRNA technology across vaccines and therapeutics development
The company has been consistently reducing debt
The data should be submitted by August 12th 2021
Total income grew in the quarter
EPS climbs to Rs 9.25 for the quarter
AstraZeneca, Sinopharm and Moderna were part of the study
Subscribe To Our Newsletter & Stay Updated